Your browser is no longer supported. Please, upgrade your browser.
PDSB PDS Biotechnology Corporation monthly Stock Chart
PDS Biotechnology Corporation
Index- P/E- EPS (ttm)-3.02 Insider Own3.80% Shs Outstand10.32M Perf Week20.96%
Market Cap30.60M Forward P/E155.38 EPS next Y0.01 Insider Trans0.00% Shs Float9.77M Perf Month41.26%
Income-17.80M PEG- EPS next Q-0.23 Inst Own10.70% Short Float1.82% Perf Quarter180.56%
Sales- P/S- EPS this Y94.50% Inst Trans- Short Ratio0.10 Perf Half Y-30.58%
Book/sh1.93 P/B1.05 EPS next Y100.90% ROA-85.20% Target Price- Perf Year-69.16%
Cash/sh1.39 P/C1.46 EPS next 5Y- ROE-105.10% 52W Range0.62 - 6.71 Perf YTD-23.77%
Dividend- P/FCF- EPS past 5Y32.40% ROI- 52W High-69.90% Beta2.90
Dividend %- Quick Ratio5.90 Sales past 5Y- Gross Margin- 52W Low228.30% ATR0.32
Employees16 Current Ratio5.90 Sales Q/Q- Oper. Margin- RSI (14)59.95 Volatility17.38% 17.49%
OptionableNo Debt/Eq0.00 EPS Q/Q-126.20% Profit Margin- Rel Volume0.20 Prev Close1.99
ShortableYes LT Debt/Eq0.00 EarningsMay 13 BMO Payout- Avg Volume1.73M Price2.02
Recom2.20 SMA2025.14% SMA5054.95% SMA2003.35% Volume352,439 Change1.51%
May-27-20Initiated Alliance Global Partners Buy $4
Mar-09-20Initiated Noble Capital Markets Outperform $5.45
Oct-24-19Initiated Chardan Capital Markets Buy $10
Jun-22-20 08:30AM  
Jun-17-20 08:30AM  
Jun-15-20 08:30AM  
Jun-14-20 11:43AM  
Jun-05-20 07:34AM  
Jun-04-20 04:05PM  
Jun-03-20 09:00AM  
Jun-02-20 08:30AM  
May-13-20 05:05PM  
May-04-20 08:30AM  
Apr-30-20 07:19AM  
Apr-29-20 04:05PM  
Apr-16-20 08:30AM  
Apr-09-20 08:30AM  
Apr-02-20 12:00PM  
Mar-27-20 04:15PM  
Mar-23-20 04:45PM  
Mar-05-20 08:30AM  
Feb-27-20 08:30AM  
Feb-24-20 08:30AM  
Feb-17-20 08:30AM  
Feb-14-20 04:05PM  
Feb-12-20 09:18AM  
Feb-11-20 06:45PM  
Feb-05-20 04:05PM  
Dec-11-19 04:15PM  
Dec-03-19 08:40AM  
Nov-25-19 08:30AM  
Nov-13-19 11:07AM  
Nov-07-19 06:00AM  
Nov-06-19 04:05PM  
Oct-22-19 08:30AM  
Oct-03-19 11:45AM  
Oct-01-19 08:30AM  
Sep-19-19 08:00AM  
Sep-03-19 08:30AM  
Aug-01-19 06:00AM  
Jul-03-19 08:30AM  
Jun-19-19 08:30AM  
May-29-19 09:41AM  
May-28-19 08:30AM  
May-17-19 12:07PM  
May-15-19 08:30AM  
May-14-19 05:22PM  
Apr-08-19 08:00AM  
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial, a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials, including PDS0102 (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104 (TRP2) for the treatment of melanoma. The company has a collaboration agreement with Merck & Co. to combine PDS0101 with Keytruda, a checkpoint inhibitor to treat human papillomavirus positive recurrent or metastatic head and neck cancer; and an agreement with Farmacore Biotechnology for the development of Versamune-based vaccine to prevent COVID-19 infection. The company is based in Princeton, New Jersey.